Addressing unmet needs in generalized pustular psoriasis: Real-world insights
As a rare and heterogeneous autoinflammatory skin disease, generalized pustular psoriasis (GPP) currently lacks clear and consistent management guidelines, presenting treatment challenges particularly for patients experiencing recurrent flares. This article highlights global GPP data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024 and reports recent case series of Chinese and Italian patients with GPP flares treated with spesolimab, an interleukin (IL)-36 receptor antagonist.
